Background The detrimental impact of dementia upon patient health-related quality of life (HRQL) is well established, as is the importance of improving HRQL. However, relatively little is known about ...

Background Early diagnosis of cognitive impairment allows timely intervention with pharmacological and non-pharmacological measures. However, current cognitive evaluation tools do not cater for ...

Objective: To report our experience with repeat microvascular decompression (MVD) for hemifacial spasm (HFS) in patients who have failed their first operation. Methods: The authors describe 41 redo ...

Introduction JC virus (JCV) seroposivity is a risk factor for the future development of progressive multifocal leukoencephalopathy in people with multiple sclerosis (MS) about to start natalizumab. In ...

Objective To determine the outcomes of combined stereo-electroencephalography-guided and MRI-guided stereotactic laser interstitial thermal therapy (LITT) in the treatment of patients with ...

Catatonia is a complex neuropsychiatric syndrome characterised by a broad range of motor, speech and behavioural abnormalities. ‘Waxy flexibility', ‘posturing' and ‘catalepsy' are among the ...

Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports ...

Hereditary haemochromatosis (HH) is a genetic disorder in which abnormal iron handling leads to excessive iron accumulation in systemic tissues. Magnetic resonance imaging studies suggest excess iron ...

Neurocysticercosis is a disease of poverty and underdevelopment. Little is known about the natural history of the infection in humans, but some of the mechanisms whereby the parasite remains silent ...

Background: Some ganglioside complexes (GSCs) are target antigens for serum antibodies in patients with Guillain–Barré syndrome (GBS). Anti-GSC antibodies may be associated with particular clinical ...

Background To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod. Methods ...

Loss of smell is a characteristic finding of COVID-19. It may outpersist the resolution of the disease, though recovery varies significantly, ranging from 15 to 180 days.1 Studies have purported ...